JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mische, C. C.
Right arrow Articles by Sodroski, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mische, C. C.
Right arrow Articles by Sodroski, J.

 Previous Article  |  Next Article 

Journal of Virology, November 2005, p. 14446-14450, Vol. 79, No. 22
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.22.14446-14450.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Retroviral Restriction Factor TRIM5{alpha} Is a Trimer

Claudia C. Mische,1 Hassan Javanbakht,1 Byeongwoon Song,1 Felipe Diaz-Griffero,1 Matthew Stremlau,1 Bettina Strack,1 Zhihai Si,1 and Joseph Sodroski1,2*

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Massachusetts 02115,1 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 021152

Received 12 May 2005/ Accepted 26 August 2005


   ABSTRACT
Top
 Abstract
Text
 References
 
The retrovirus restriction factor TRIM5{alpha} targets the viral capsid soon after entry. Here we show that the TRIM5{alpha} protein oligomerizes into trimers. The TRIM5{alpha} coiled-coil and B30.2(SPRY) domains make important contributions to the formation and/or stability of the trimers. A functionally defective TRIM5{alpha} mutant with the RING and B-box 2 domains deleted can form heterotrimers with wild-type TRIM5{alpha}, accounting for the observed dominant-negative activity of the mutant protein. Trimerization potentially allows TRIM5{alpha} to interact with threefold pseudosymmetrical structures on retroviral capsids.


   TEXT
Top
 Abstract
 Text
References
 
TRIM5{alpha} is a constitutively expressed cytoplasmic protein that allows the cells of primates to resist infection by particular retroviruses, including human immunodeficiency virus type 1 (HIV-1) (10, 14, 25, 31, 32, 37). TRIM5{alpha} is thought to target the incoming retroviral capsid soon after entry into the cells (9, 11, 13, 15, 19, 21, 22, 29, 34). The specific mechanism by which TRIM5{alpha} restricts retroviral infection remains unknown.

TRIM5{alpha} is a member of the tripartite motif (TRIM) family of proteins which contain RING, B-box, and coiled-coil domains (26). Many TRIM proteins self-associate to form homo-oligomers; less frequently, hetero-oligomerization is observed (26). Structural predictions suggest that the coiled coils of TRIM proteins exhibit a propensity to form both dimers and trimers (6, 7, 17). There is only limited information available about the oligomeric state of TRIM proteins. Oligomerization has been shown to be important for the function of the nuclear TRIM28 (KAP-1) protein (23, 24). In this case, the RING, B-box, and coiled-coil domains were shown to contribute to trimerization. The coiled coil of TRIM7 is essential for oligomerization (39). Here we examine the oligomeric state of TRIM5.

The hemagglutinin (HA)-tagged TRIM5 variants in Fig. 1A were expressed transiently in 293T cells or stably in HeLa cells. Cells were washed in phosphate-buffered saline (PBS) and lysed in NP-40 lysis buffer (0.5% Nonidet P40 [NP-40], 1 x complete EDTA-free protease inhibitor [Roche Diagnostics] in PBS) for 45 min at 4°C. Lysates were centrifuged at 14,000 x g for 15 min at 4°C. The cleared lysates were not stored or frozen but rather were directly cross-linked. Approximately 100 to 200 µl of cleared lysates was diluted with PBS plus 1 mM EDTA to a final volume of 400 µl. Lysates were cross-linked with various concentrations (up to 10 mM) of glutaraldehyde (GA) for 5 min at room temperature and centrifuged briefly in a table-top centrifuge. The reaction mix was quenched with 0.1 M Tris-HCl, pH 7.5, and briefly centrifuged. The cleared, cross-linked lysates were precipitated with the anti-HA antibody HA.11 (Covance) and protein A-Sepharose beads (Amersham) for 2 h at 4°C; final volumes for the immunoprecipitation were greater than 700 µl. The beads were washed four times with NP-40 wash buffer (10 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.5% NP-40) and boiled in LDS sample buffer (106 mM Tris-HCl, 141 mM Tris base, pH 8.5, 0.51 mM EDTA, 10% glycerol, 2% LDS, 0.22 mM SERVA Blue G250, 0.175 mM phenol red [Invitrogen]) with different concentrations of ß-mercaptoethanol (ß-ME) for 10 min. Precipitated proteins were separated on 8% or 12% Tris-glycine gels, transferred to a polyvinylidene difluoride membrane, and detected with the horseradish peroxidase-conjugated 3F10 anti-HA antibody (Roche Diagnostics) and the ECL Plus Western blotting detection system (Amersham).



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 1. Oligomeric state of rhesus monkey TRIM5{alpha} variants. (A) A diagram of the TRIM5{alpha}rh protein with the carboxy-terminal HA tag is shown, with the domains labeled and domain boundaries numbered according to the amino acid residue. The amino-terminal truncation mutants and TRIM5{gamma}rh are depicted beneath the wild-type TRIM5{alpha}rh. (B) HeLa cells stably expressing the indicated TRIM5{alpha}rh variants or 293T cells expressing the TRIM5{alpha}rh-HA {Delta}297 mutant were lysed and cross-linked with different concentrations (mM) of GA. After precipitation with an anti-HA antibody, samples were boiled in LDS sample buffer with 0.01% ß-mercaptoethanol prior to gel electrophoresis and Western blotting with an anti-HA antibody. m, monomer; d, dimer; t, trimer. Molecular mass markers (in kDa) are indicated. (C) The TRIM5{alpha}-HA {Delta}93 and TRIM5{alpha}rh-HA {Delta}132 proteins were stably expressed in HeLa cells, which were lysed, treated with GA, and used for immunoprecipitation as described for panel B. The precipitated proteins were boiled in LDS sample buffer with 2.5% ß-mercaptoethanol, analyzed on gels, and Western blotted as described for panel B. m, monomer; d, dimer; t, trimer.

 
TRIM5 isoforms include TRIM5{gamma}, which consists of the RING, B-box 2, and coiled-coil domains, and TRIM5{alpha}, which contains an additional C-terminal B30.2(SPRY) domain (26). The wild-type rhesus monkey TRIM5{alpha}rh protein exhibited a molecular mass of 54 to 56 kDa, consistent with that of a monomer (Fig. 1B). Only a small amount of a higher-order form, probably a dimer, was evident in the absence of cross-linker. This putative dimer was sensitive to ß-ME (data not shown). Cross-linking with increasing GA concentrations resulted in the progressive appearance of a 156- to 164-kDa species, consistent with a trimer. By contrast, TRIM5{gamma}rh exhibited a dimeric form both without and with GA treatment. Higher-order forms of TRIM5{gamma}rh were evident after GA cross-linking, although trimers were not a dominant species. As TRIM5{alpha}rh and TRIM5{gamma}rh share 300 amino-terminal residues, these results suggest that the TRIM5{alpha}rh sequences carboxy terminal to residue 300 can significantly affect the oligomerization state of the protein.

The oligomeric states of several TRIM5{alpha}rh mutants lacking one or more domains was examined. TRIM5{alpha}rh-HA {Delta}297, which consists of the B30.2(SPRY) domain alone, migrated as a monomer even after GA cross-linking (Fig. 1B). TRIM5{alpha}rh-HA {Delta}93, which lacks the RING domain, and TRIM5{alpha}rh-HA {Delta}132, which lacks the RING and B-box 2 domains, exhibited similar patterns upon GA cross-linking. A species consistent with a dimer was evident in the absence of cross-linker and after GA treatment of both proteins. This form was most apparent when the sample buffer contained low ß-ME concentrations (Fig. 1B) and was less evident when larger amounts of ß-ME were included in the sample buffer (Fig. 1C). We suspect that these gel-stable dimers result from artifactual oxidation of exposed TRIM5{alpha} cysteines upon cell lysis. Forms consistent with trimers were apparent for both TRIM5{alpha}rh-HA {Delta}93 and TRIM5{alpha}rh-HA {Delta}132 proteins after GA cross-linking (Fig. 1B). Treatment of the samples with higher concentrations of ß-ME demonstrated that the major higher-order product cross-linked by GA for both proteins was a trimer (Fig. 1C). Thus, the TRIM5{alpha}rh segment that includes the coiled coil and the B30.2(SPRY) domain is sufficient for trimerization.

The efficiency with which all three subunits of the wild-type TRIM5{alpha} oligomer were cross-linked into gel-stable trimers suggested that many potential GA-reactive sites exist in the TRIM5{alpha} subunits. Consistent with this, the use of another cross-linker, EGS [ethylene glycolbis(succinimidylsuccinate)], allowed visualization of gel-stable dimers as well as trimers (Fig. 2A).



View larger version (38K):
[in this window]
[in a new window]
  		FIG. 2. TRIM5{alpha}rh trimerization and formation of heterotrimers. (A) 293T cells transiently expressing TRIM5{alpha}rh-HA were lysed and the cell lysates treated with the indicated concentrations of GA or EGS. After precipitation with an anti-HA antibody, samples were boiled in LDS sample buffer with 2.5% ß-mercaptoethanol prior to gel electrophoresis and Western blotting with an anti-HA antibody. m, monomer, d, dimer, t, trimer. Molecular mass markers (in kDa) are indicated. (B) 293T cells transiently expressing the wild-type (w.t.) TRIM5{alpha}rh-HA protein, TRIM5{alpha}rh-HA {Delta}132, or a mixture of both proteins were lysed. Cell lysates were incubated in the absence of GA (–GA) or with 0.25 mM GA and then used for immunoprecipitation and Western blotting with an anti-HA antibody as described above. The gel-stable homodimers are labeled (w.t.)2 or ({Delta}132)2 and the gel-stable homotrimers (w.t.)3 or ({Delta}132)3. The positions of the heterodimer (hd) and heterotrimers (ht) are indicated. Molecular mass markers (in kDa) are indicated.

 
TRIM5{alpha} mutants lacking the RING and B-box 2 domains have been shown to associate with wild-type TRIM5{alpha} and exert dominant-negative activity on retrovirus restriction (13a, 24a). Coexpression of the wild-type TRIM5{alpha}rh-HA and TRIM5{alpha}rh-HA {Delta}132 proteins resulted in the formation of heterotrimers; small amounts of gel-stable heterodimers and heterotrimers were evident in the absence of cross-linker (Fig. 2B, left panel). Cross-linking with GA increased the amounts of detectable heterotrimers (Fig. 2B, right panel).

TRIM5 protein variants from other monkey species were examined. The TRIM5{alpha} proteins from two subspecies of African green monkey also predominantly formed trimers detectable by cross-linking (Fig. 3A). Owl monkeys, a New World species, do not express a TRIM5{alpha} protein but instead express TRIMCyp, which consists of the RING, B-box 2, and coiled-coil domains of TRIM5 fused with cyclophilin A (20, 28). TRIMCyp restricts HIV-1 infection in owl monkey cells. Upon GA cross-linking, TRIMCyp exhibited mostly very-high-molecular-weight species as well as a lower level of trimers (Fig. 3B). These results support an effect of the carboxy-terminal TRIM5 sequences on the oligomeric state of the protein.



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 3. Oligomeric state of TRIM5 variants from other monkey species. HeLa cells stably expressing TRIM5{alpha} proteins from African green monkeys (AGM), either the tantalus (tan) or pygerythrus (pyg) subspecies (A) or the owl monkey TRIMCyp protein (B) were lysed. Cell lysates were cross-linked with the indicated concentrations of GA and precipitated with an anti-HA antibody. Precipitated proteins were boiled in LDS sample buffer with 2.5% ß-mercaptoethanol and analyzed by Western blotting with an anti-HA antibody. Molecular mass markers are indicated. m, monomer; d, dimer; t, trimer.

 
We have demonstrated that the TRIM5{alpha} proteins from three Old World monkey species, all of which have been shown to restrict HIV-1 infection (1, 8, 11, 12), exist as trimers. The coiled-coil and B30.2(SPRY) domains of TRIM5{alpha}rh are sufficient for trimerization. As expected from studies of other TRIM proteins (23, 24, 26), the TRIM5{alpha}rh coiled coil apparently contributes to homo-oligomerization. This conclusion is supported by our observation that TRIM5{alpha}rh-HA {Delta}132 can form trimers, whereas TRIM5{alpha}rh-HA {Delta}297 is a monomer.

Surprisingly, the carboxyl terminus of TRIM5 influences the oligomerization state of variants with identical or closely related RING, B-box 2, and coiled-coil domains. TRIM5{gamma}rh, which lacks the B30.2(SPRY) domain of the trimeric TRIM5{alpha} isoform, formed dimers and some higher-order species but few or no trimers. TRIMCyp, in which the B30.2 domain is replaced by a cyclophilin A moiety (20, 28), formed some trimers but mostly a higher-order entity, possibly a dimer of trimers.

The capsid protein of retroviruses determines susceptibility to restriction by a particular TRIM5{alpha} protein (2, 9, 15, 21, 22, 34). Thus, the retroviral capsid likely binds TRIM5{alpha}, a model supported by the observation that virus-like particles with mature capsids can compete for restriction factors in the target cell (1-3, 19). Retroviral capsids are composed of hexamers that, through dimeric contacts, assemble into large arrays (5, 16, 18). Retroviral capsids, although organized into these large assemblies, are intrinsically asymmetric. Retroviral capsids thus contain imperfect twofold- and threefold-symmetry axes. Interestingly, cryoelectron microscope studies of the HIV-1 capsid have revealed two types of holes in the capsid surface: a roughly cylindrical hole formed at the center of the hexameric ring and a trilobed hole flanked by the spokes of the hexamers (Fig. 4) (16). Both holes are centered at threefold pseudosymmetry axes and could serve as potential TRIM5{alpha} binding sites. In both proposed modes of TRIM5{alpha} binding (Fig. 4), each of the lobes of the trilobed pocket accommodates a TRIM5{alpha} B30.2 domain, which has been implicated in the determination of TRIM5 antiviral potency (27, 33, 38). Some evidence appears to favor the trilobed hole as a TRIM5{alpha} binding site. Cyclophilin A, which has been reported to modulate TRIM5{alpha}-mediated restriction (9, 13, 21, 30, 35), binds the HIV-1 capsid near the threefold axis associated with the trilobed holes (4, 36). Moreover, the location of amino acid changes in the HIV-1 capsid that influence susceptibility to TRIM5{alpha} restriction (9, 13, 15, 21) is consistent with a model in which a trimeric TRIM5{alpha} protein binds in the trilobed hole. Future studies will test the validity of these models of TRIM5{alpha}-capsid interaction.



View larger version (57K):
[in this window]
[in a new window]
  		FIG. 4. Possible modes for binding a retroviral capsid with a trimeric TRIM5{alpha} protein. The cryoelectron tomographic reconstruction of the HIV-1 capsid reported by Li et al. (16) is shown. Two holes on the capsid surface, each centered on threefold axes of pseudosymmetry, exist. A nearly cylindrical hole is formed by the ring of hexameric capsid proteins (blue). A possible binding mode in this region is depicted by the yellow ovoids, each representing a TRIM5{alpha} B30.2 domain. In this binding mode, the trimeric axis of TRIM5{alpha} would intersect the capsid surface at the position indicated by the yellow dot. A second possible binding mode involves the trilobed hole formed by three adjacent capsid hexamers (shaded red). A possible binding mode of three TRIM5{alpha} B30.2 domains (green) in this trilobed hole is shown. In this binding mode, the TRIM5{alpha} trimeric axis would intersect the capsid surface at the position indicated by the green dot.

 


   ACKNOWLEDGMENTS
 
We thank Yvette McLaughlin and Sheri Farnum for manuscript preparation.

We acknowledge the support of grants (AI063987 and HL54785) from the National Institutes of Health and a Center for AIDS Research Award (AI28691). We also acknowledge the support of the International AIDS Vaccine Initiative, the Bristol-Myers Squibb Foundation, the William A. Haseltine Foundation for the Arts and Sciences, and the late William F. McCarty-Cooper. H.J. was supported by a fellowship from the Canadian Institutes of Health Research.


   FOOTNOTES
 
* Corresponding author. Mailing address: Dana-Farber Cancer Institute, 44 Binney Street, JFB 824, Boston, MA 02115. Phone: (617) 632-3371. Fax: (617) 632-4338. E-mail: joseph_sodroski{at}dfci.harvard.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Besnier, C., Y. Takeuchi, and G. Towers. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. USA 99:11920-11925.[Abstract/Free Full Text]
  2. Cowan, S., T. Hatziioannou, T. Cunningham, M. A. Muesing, H. G. Gottlinger, and P. D. Bieniasz. 2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA 99:11914-11919.[Abstract/Free Full Text]
  3. Forshey, B. M., J. Shi, and C. Aiken. 2005. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J. Virol. 79:869-875.[Abstract/Free Full Text]
  4. Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294.[CrossRef][Medline]
  5. Ganser, B. K., S. Li, V. Y. Klishko, J. T. Finch, and W. I. Sundquist. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83.[Abstract/Free Full Text]
  6. Harbury, P. B., B. Tidor, and P. S. Kim. 1995. Repacking protein cores with backbone freedom: structure prediction for coiled coils. Proc. Natl. Acad. Sci. USA 92:8408-8412.[Abstract/Free Full Text]
  7. Harbury, P. B., T. Zhang, P. S. Kim, and T. Alber. 1993. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401-1407.[Abstract/Free Full Text]
  8. Hatziioannou, T., S. Cowan, S. P. Goff, P. D. Bieniasz, and G. J. Towers. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-394.[CrossRef][Medline]
  9. Hatziioannou, T., S. Cowan, U. K. Von Schwedler, W. I. Sundquist, and P. D. Bieniasz. 2004. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78:6005-6012.[Abstract/Free Full Text]
  10. Hatziioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc. Natl. Acad. Sci. USA 101:10774-10779.[Abstract/Free Full Text]
  11. Himathongkham, S., and P. A. Luciw. 1996. Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology 219: 485-488.[CrossRef][Medline]
  12. Hofmann, W., D. Schubert, J. LaBonte, L. Munson, S. Gibson, J. Scammell, P. Ferrigno, and J. Sodroski. 1999. Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 73:10020-10028.[Abstract/Free Full Text]
  13. Ikeda, Y., L. M. Ylinen, M. Kahar-Bador, and G. J. Towers. 2004. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J. Virol. 78:11816-11822.[Abstract/Free Full Text]
  14. Javanbakht, H., F. Diaz-Griffero, M. Stremlau, Z. Si, and J. Sodroski. 2005. The contribution of RING and B-box 2 domains to retroviral mediated by monkey TRIM5alpha. J. Biol. Chem. 280:26933-26940.[Abstract/Free Full Text]
  15. Keckesova, Z., L. M. Ylinen, and G. J. Towers. 2004. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101:10780-10785.[Abstract/Free Full Text]
  16. Kootstra, N. A., C. Munk, N. Tonnu, N. R. Landau, and I. M. Verma. 2003. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. USA 100:1298-1303.[Abstract/Free Full Text]
  17. Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch. 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409-413.[CrossRef][Medline]
  18. Lupas, A., M. Van Dyke, and J. Stock. 1991. Predicting coiled coils from protein sequences. Science 252:1162-1164.[CrossRef][Medline]
  19. Mortuza, G. B., L. F. Haire, A. Stevens, S. J. Smerdon, J. P. Stoye, and I. A. Taylor. 2004. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431:481-485.[CrossRef][Medline]
  20. Munk, C., S. M. Brandt, G. Lucero, and N. R. Landau. 2002. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. USA 99:13843-13848.[Abstract/Free Full Text]
  21. Nisole, S., C. Lynch, J. P. Stoye, and M. W. Yap. 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. USA 101:13324-13328.[Abstract/Free Full Text]
  22. Owens, C. M., B. Song, M. J. Perron, P. C. Yang, M. Stremlau, and J. Sodroski. 2004. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 78:5423-5437.[Abstract/Free Full Text]
  23. Owens, C. M., P. C. Yang, H. Gottlinger, and J. Sodroski. 2003. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J. Virol. 77:726-731.
  24. Peng, H., G. E. Begg, D. C. Schultz, J. R. Friedman, D. E. Jensen, D. W. Speicher, and F. J. Rauscher III. 2000. Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions. J. Mol. Biol. 295:1139-1162.[CrossRef][Medline]
  25. Peng, H., I. Feldman, and F. J. Rauscher III. 2002. Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. J. Mol. Biol. 320:629-644.[CrossRef][Medline]
  26. Perez-Caballero, D., T. Hatziioannou, A. Yang, S. Cowan, and P. D. Bieniasz. 2005. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J. Virol. 79:8969-8978.[Abstract/Free Full Text]
  27. Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski. 2004. TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 101: 11827-11832.[Abstract/Free Full Text]
  28. Reymond, A., G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.[CrossRef][Medline]
  29. Sawyer, S. L., L. I. Wu, M. Emerman, and H. S. Malik. 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. USA 102:2832-2837.[Abstract/Free Full Text]
  30. Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.[CrossRef][Medline]
  31. Shibata, R., H. Sakai, M. Kawamura, K. Tokunaga, and A. Adachi. 1995. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol. 76:2723-2730.[Abstract/Free Full Text]
  32. Sokolskaja, E., D. M. Sayah, and J. Luban. 2004. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78:12800-12808.[Abstract/Free Full Text]
  33. Song, B., H. Javanbakht, M. Perron, D. H. Park, M. Stremlau, and J. Sodroski. 2005. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J. Virol. 79:3930-3937.[Abstract/Free Full Text]
  34. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.[CrossRef][Medline]
  35. Stremlau, M., M. Perron, S. Welikala, and J. Sodroski. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J. Virol. 79:3139-3145.[Abstract/Free Full Text]
  36. Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos. 2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA 97:12295-12299.[Abstract/Free Full Text]
  37. Towers, G. J., T. Hatziioannou, S. Cowan, S. P. Goff, J. Luban, and P. D. Bieniasz. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143.[CrossRef][Medline]
  38. Vajdos, F. F., S. Yoo, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1997. Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci. 6:2297-2307.[Abstract]
  39. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.[Abstract/Free Full Text]
  40. Yap, M. W., S. Nisole, and J. P. Stoye. 2005. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15:73-78.[CrossRef][Medline]
  41. Zhai, L., A. Dietrich, A. V. Skurat, and P. J. Roach. 2004. Structure-function analysis of GNIP, the glycogenin-interacting protein. Arch. Biochem. Biophys. 421:236-242.[CrossRef][Medline]

Journal of Virology, November 2005, p. 14446-14450, Vol. 79, No. 22
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.22.14446-14450.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mische, C. C.
Right arrow Articles by Sodroski, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mische, C. C.
Right arrow Articles by Sodroski, J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS